Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

OncoSec Medical Inc (ONCS) USD0.0001

Sell:$3.63 Buy:$3.70 Change: $0.01 (0.27%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Change: $0.01 (0.27%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Change: $0.01 (0.27%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company’s lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO).

Contact details

24 N Main St
United States
+1 (858) 2107333

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$102.08 million
Shares in issue:
23.05 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Margaret Dalesandro
    Independent Chairman of the Board
  • Daniel O'Connor
    President, Chief Executive Officer, Director
  • Kellie Foerter
    Chief Operating Officer, Chief Clinical Development Officer
  • Robert DelAversano
    Principal Accounting Officer, Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.